ArticleFrontiers in nutrition2025
"Hot" alkaline hydrolysis of UiO-66 to enhance quercetin loading,
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Food and Drug Administration (FDA) classifies quercetin (QU) as a generally recognized as safe (GRAS) substance and exhibits striking antioxidant and anti-inflammatory activities. However, its extremely low solubility in water limits its application in the fields of food and nutrition. Nanomaterials such as UiO-66 (University of Oslo 66) have been widely used in the field of nutrient delivery. Methods: In this study, terephthalic acid ligands were stripped from small-sized UiO-66 via a thermal alkaline hydrolysis method, resulting in a new drug-loaded material, UiO-66-BH-100 (UiO-66 blended and heated, with a size of 100 nm). The obtained UiO-66-BH-100 showed significantly increased porosity and good thermal stability. UiO-66-BH-100, which is rich in hydroxyl groups (1.7 × 1019/m Results: The QU-loaded drug carrier UiO-66-BH-100@QU has good biocompatibility and could significantly improve the in vitro release behavior of QU. Notably, the capacity of UiO-66-BH-100@QU to scavenge diphenyl-2-picrylhydrazyl (DPPH) and 22'-azinobis (3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS), as well as its ability to inhibit NO secretion, was almost comparable to that of QU, demonstrating promising antioxidant and anti-inflammatory potential. Conclusion: This study provides a simple and effective new approach for delivering natural active ingredients with excellent bioavailability in the field of functional foods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.